Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03043287 · ClinicalTrials.gov registry record
Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)
A clinical trial, sponsored by Allergan.
- Completed
- Registry status
- 420
- Enrollment target
NCT03043287: Completed study, sponsored by Allergan.
NCT03043287 is a clinical trial that has completed, run by Allergan. The registered enrollment target is 420 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03043287 has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- 420 participants
- Enrollment target
Study Summary
This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.
Primary Outcome
VE was calculated as the ratio of voided volume to the total bladder capacity.
Interventions
- BIOLOGICAL onabotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2017-05-12 |
| Est. Completion | 2019-09-30 |
What the finished NCT03043287 record still lists
NCT03043287 is an observational study that tracks outcomes without assigning an intervention. The registered 420 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which onabotulinumtoxinA is the first listed.
NCT03043287 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03043287 about?
NCT03043287 is a clinical study titled "Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)". This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.
What is the current status of trial NCT03043287?
This trial is currently completed. The enrollment target is 420 participants. The study started on 2017-05-12. Estimated completion is 2019-09-30.
What interventions are being tested in trial NCT03043287?
The interventions under investigation include: onabotulinumtoxinA (BIOLOGICAL).
Who is sponsoring clinical trial NCT03043287?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01790152 · 420 participants
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- NCT02701244 · 420 participants
A Registry Study of Breast Microseed Treatment
- NCT02966665 · 420 participants · Phase 1
: Vascular Function in Health and Disease
- NCT04149743 · 420 participants · NA
HEMOTAG® Assessment for Short-term Outcomes of Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI